Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial
Published Online: 2022-01-?
Journal: The Lancet•Publisher: Elsevier BV
Authors: Aamer Ikram•Amalia Guadalupe Becerra Aquino•Bernardo Goecke•Bruce Smith•Cesar Zaidman•Dmitry A Lioznov•Donna MacKinnon-Cameron•Edgar Eduardo Saldaña Montemayor•Eduardo López•Ejaz Ahmed Khan•Elena Rozhkova•Felipe de Jesús Pineda Cárdenas•Fengcai Zhu•Fernando Lanas•Ghazala Parveen•Gonzalo Corral•Guillermo M Ruiz-Palacios•Gustavo Lopardo•Helen Mao•J. Abraham Simón Campos•Jayed Akram•Jinbo Gou•Joanne M Langley•Laura Leppan•Lihua Hou•Lingyun Ye•Luc Gagnon•Luis Barreto•M Lourdes Guerrero•Maria F. Alzogaray•Naseem Salahuddin•Norma Eréndira Rivera Martínez•Omar Sued•Pedro E Cahn•Ricardo Teijeiro•Rosa María Feijooó Seoane•Salma Abbas•Sarwat Tahsin Khan•Sayed Faisal Mahmood•Scott A Halperin•Sergio Raúl Muñoz Navarro•Steven-Phay Tran•Tao Zhu•Tatyana Zubkova•Vitalina Dzutseva•Víctor Casildo Bohórquez López•Wei Chen•Zhe Zhang
